ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced corporate highlights and unaudited financial results for the first half of 2025.
Related Questions
How did the H1 2025 financial results compare to consensus estimates and what are the implications for the stock price?
What are the key clinical milestones announced in the pipeline and how might they affect the company's valuation and risk profile?
What is the company's cash runway and any planned financing or partnership activities that could dilute shareholders or impact liquidity?